Co-morbidity burden in Parkinson’s disease : Comparison with controls and its influence on prognosis
Citation
MacLeod , A D , Goddard , H & Counsell , C E 2016 , ' Co-morbidity burden in Parkinson’s disease : Comparison with controls and its influence on prognosis ' Parkinsonism & Related Disorders , vol. 28 , pp. 124-129 . DOI: 10.1016/j.parkreldis.2016.05.013
Rights
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Related items
Showing items related by title, author, creator and subject.
-
Statins are underused in recent-onset Parkinson's disease with increased vascular risk : findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts
Swallow, Diane M A; Lawton, Michael A; Grosset, Katherine A; Malek, Naveed; Klein, Johannes; Baig, Fahd; Ruffmann, Claudio; Bajaj, Nin P; Barker, Roger A; Ben-Shlomo, Yoav; Burn, David J; Foltynie, Thomas; Morris, Huw R; Williams, Nigel; Wood, Nicholas W; Hu, Michele T M; Grosset, Donald G (2016-11) -
The Mini-Mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease
Caslake, Robert; Summers, Fiona; McConachie, Douglas; Ferris, Catriona; Gordon, Joanna; Harris, Clare; Caie, Linda; Counsell, Carl (2013-11-30) -
Evidence for a Role of Adaptive Immune Response in the Disease Pathogenesis of the MPTP Mouse Model of Parkinson’s Disease
Martin, Heather L.; Santoro, Matteo; Mustafa, Sarah; Riedel, Gernot; Forrester, John V.; Teismann, Peter (2016-03)